Table 1.
Characteristics of individuals included in the analysis
| Infection/Vaccine status |
||||||
|---|---|---|---|---|---|---|
| −/2/− |
+/2/− |
−/3/− |
+/3/− |
−/3/+ |
+/3/+ |
|
| n = 14 | n = 12 | n = 19 | n = 10 | n = 16 | n = 5 | |
| Age (years), median [IQR] | 45 [28–52] | 43 [35–51] | 42 [26–48] | 37 [24–49] | 49 [35–51] | 43 [38–49] |
| Sex (% female) | 78.6 | 66.7 | 73.7 | 70.0 | 75.0 | 100.0 |
| Time between the first plasma sample collection and the indicated event (median days [IQR]): | ||||||
| Last vaccine dose | 34 [32–38] | 34 [14–46] | 34 [31–37] | 33 [31–41] | 90 [60–92] | 35 [32–70] |
| Pre-vaccine infection | NA | 336 [153–360] | NA | 588 [459–662] | NA | 621 [424–677] |
| Post-vaccine infection | NA | NA | NA | NA | 35 [18–43] | 25 [13–38] |
| Time between the second plasma sample collection and the indicated event (median days [IQR]): | ||||||
| Last vaccine dose | 183 [177–197] | 200 [176–223] | 92 [91–99] | 92 [91–104] | NA | NA |
| Pre-vaccine infection | NA | 488 [333–529] | NA | 697 [502–725] | NA | NA |
Groups are named according to their SARS-CoV-2 infection status prior to infection (+ or –), the number of vaccines received (2 or 3) and the occurrence of breakthrough infection (+ or –).